Sciatica and nerve pain medicines: what a review found

Gabapentin and pregabalin are among the medicines people with sciatica are most often handed when the pain runs down the leg and will not settle. A new review published this month looked at how well that whole family of nerve pain medicines actually works, and the finding underneath the summary is worth sitting with.

The paper, an umbrella review in Current Neuropharmacology, did not run a fresh trial. It gathered the existing systematic reviews and meta analyses on gabapentinoids for nerve pain, twenty two of them in all, and graded how trustworthy each one was (Current Neuropharmacology, 2026). That grading is the first quiet result. Nineteen of the twenty two reviews came out as critically low quality on the standard tool the authors used, which they said lowers confidence in any claim about how well these medicines work.

The second result is where the medicines seemed to help and where they did not. The review reported clearer signals of benefit for diabetic nerve pain, for cancer related nerve pain, and for pain after spinal cord injury. Sciatica was one of the six conditions it examined. It did not appear in that shorter list. Across the board the authors also noted the familiar trade, that these medicines are strongly associated with drowsiness, dizziness, fluid retention, and weight gain.

If you have sciatica, that pattern is not new. It is the latest layer on a picture that has been forming for years.

What the headline leaves out

The headline version of a review like this is simple: nerve pain medicines, studied again. What that framing hides is that for sciatica in particular, the strongest single trial we have already answered the question, and the answer was no. In a randomized trial in the New England Journal of Medicine, pregabalin did not reduce leg pain in people with sciatica compared with a placebo, and the people taking it reported more side effects (New England Journal of Medicine, 2017). The gap between the two groups at eight weeks was half a point on a scale of zero to ten, small enough to sit inside the noise. An earlier meta analysis pooling the sciatica trials reached the same place, that the routine use of gabapentin and pregabalin for sciatica pain cannot be supported (Atención Primaria, 2021).

Guidance has already caught up with that evidence. The National Institute for Health and Care Excellence, which writes the treatment guidelines used across the United Kingdom, advises clinicians not to offer gabapentinoids for sciatica, citing no overall evidence of benefit and evidence of harm (NICE, 2020). So the honest reading of this month's review is not that a door opened. It is that a door most of the field had already closed stayed closed, and the new work adds another reason to trust that it should.

This is not a reason to change anything on your own

None of this is a cue to stop a medicine or adjust a dose without help. If you are taking one of these, that is a decision to revisit with the prescriber who knows your history, not with an article. Some people are managing more than one kind of pain at once, and the calculus is theirs to make together. What the evidence does do is shift where the hope is worth placing. If a medicine designed for nerve pain is, for sciatica, mostly buying side effects, then the question of what to do in the body does not disappear when the prescription runs out. It becomes the more important question.

This is the part I sit with most as a practitioner. I teach the Feldenkrais Method®, which is movement education rather than treatment, so I am careful about what I claim. But I can tell you what I see. With sciatica, what people most often lose is not movement itself. It is the trust that movement will help. The leg pain is frightening in a way that ordinary aches are not, so the whole body starts to guard, the walk shifts, the breath shortens, and the guarding becomes its own second problem laid over the first. Our Feldypedia entry on sciatica and nerve related back pain walks through that cycle of fear and avoidance, and the entry on chronic lower back pain covers the same trap from a wider angle.

What gentle, attentive movement offers here is not a stronger painkiller. It is a way back into that lost trust. Lying on the floor, making movements so small and slow that the nerve is never provoked, noticing how the pelvis and hips can take up some of the work the lower back has been doing alone, a person begins to feel that they have more options than the pain has been telling them. In Awareness Through Movement® lessons you only go where it feels easy, pleasant, and comfortable, which for an irritated nerve is exactly the right instruction. This kind of work sits alongside the physiotherapy or clinical care someone is already receiving, not in place of it, and it asks nothing of a prescription pad.

The medicines will keep being studied, and the evidence for sciatica may yet shift. Until it does, the more durable move is the one that was always available. Not a better drug for the leg, but a patient return to moving the whole self with less fear. That, more than anything a review can hand you, tends to be where the change begins.